SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

News in brief

J&J hunting for new CMO for Doxil

28-Sep-2011
Last updated on 28-Sep-2011 at 10:47 GMT

Supplies of Johnson & Johnson’s Doxil cancer drug will be cut down in coming months as the company transitions to a new manufacturer.

In a letter recently posted on its website, J&J told doctors to expect a limited supply because the contract manufacturing organisation (CMO) currently producing the drug was moving out of the manufacturing biz.

Its current ‘speciality manufacturer’ is battling to increase production of the drugs over the next six weeks, however J&J has warned the amount will not be sufficient for all patients on the waiting lists.

The news comes after the New Jersey-based firm told doctors not to begin treating patients with Doxil in July.

At the time Doxil boasted annual sales figures of $500m (€367m).

The company is now working on finding a new CMO to produce the injectable.

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE

Key Industry Events

 

Access all events listing

Our events, Events from partners...

On demand Supplier Webinars

A brief history of bioavailability
William Reed Business Media
Bioavailability market dynamics
William Reed Business Media
All supplier webinars